Glucagon-like peptide-1 receptor agonists before upper gastrointestinal endoscopy and risk of pulmonary aspiration or discontinuation of procedure: cohort study
In this comparative cohort study, no increased risk of pulmonary aspiration during upper gastrointestinal endoscopy was observed among adults with type 2 diabetes using GLP-1 receptor agonists compared with SGLT-2 inhibitors within 30 days of the procedure; however, GLP-1 receptor agonists were associated with a higher risk of discontinuation of endoscopy, possibly owing to a higher risk of retained gastric content. In the absence of evidence from randomized trials, these findings could inform future practice recommendations on the preprocedural protocol for patients requiring endoscopy.
Authors
- Wajd Alkabbani (ORCID: https://orcid.org/0000-0002-7030-0442)
- Karine Suissa (ORCID: https://orcid.org/0000-0003-3922-3853)
- Ion A. Hobai (ORCID: https://orcid.org/0000-0002-0567-6873)
- KRISTINE D. GU
- Elisabetta Patorno (ORCID: https://orcid.org/0000-0002-8809-9898)
- Christopher C. Thompson (ORCID: https://orcid.org/0000-0002-6105-5270)
- Deborah J. Wexler (ORCID: https://orcid.org/0000-0001-6979-402X)
- Katsiaryna Bykov (ORCID: https://orcid.org/0000-0003-3336-5412)
- SARA JANE CROMER (ORCID: https://orcid.org/0000-0002-4924-2049)
- Julie M. Paik (ORCID: https://orcid.org/0000-0002-1315-5445)
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- VA Boston Healthcare System (US)
- Massachusetts General Hospital (US)
- Geriatric Research Education and Clinical Center (US)
Publication Details
- Journal
- BMJ
- Published
- 2024-10-22
- DOI
- https://doi.org/10.1136/bmj-2024-080340
- Citations
- 45
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 18.85
Funders
- American Diabetes Association
- Brigham and Women's Hospital
- Patient-Centered Outcomes Research Institute
- National Institutes of Health
- Food and Drug Administration
- National Institute on Aging
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute of Arthritis and Musculoskeletal and Skin Diseases